Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz Sells 6,837 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 6,837 shares of the stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $47.92, for a total value of $327,629.04. Following the completion of the sale, the chief executive officer now directly owns 125,022 shares of the company’s stock, valued at approximately $5,991,054.24. This represents a 5.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Christopher Peetz also recently made the following trade(s):

• On Tuesday, January 7th, Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock opened at $48.48 on Tuesday. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $49.40. The firm has a fifty day simple moving average of $43.76 and a 200-day simple moving average of $41.61. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of -24.00 and a beta of 0.98.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company had revenue of $90.38 million during the quarter, compared to analysts’ expectations of $81.99 million. During the same period in the prior year, the company earned ($0.57) earnings per share. The business’s quarterly revenue was up 89.4% compared to the same quarter last year. On average, sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -1.45 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Amalgamated Bank grew its stake in shares of Mirum Pharmaceuticals by 60.8% in the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after acquiring an additional 513 shares during the last quarter. R Squared Ltd acquired a new stake in Mirum Pharmaceuticals in the 4th quarter worth $69,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after purchasing an additional 318 shares during the period. Avanza Fonder AB acquired a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at about $189,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Mirum Pharmaceuticals during the third quarter worth about $215,000.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on MIRM. Robert W. Baird upped their price target on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Citigroup lifted their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Leerink Partners increased their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Mirum Pharmaceuticals has an average rating of “Buy” and an average price target of $57.10.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.